Integro Theranostics

Executive Summary

Integro Theranostics is a clinical-stage biotechnology company advancing intraoperative molecular imaging (IMI) to address the critical challenge of incomplete tumor resection during cancer surgery. Its proprietary platform combines the fluorescent imaging agent Cronexitide Lanocianine (CXL) with wearable CancerVision® Goggles, enabling surgeons to visualize cancerous tissue in real-time with enhanced precision. By integrating AI/machine learning, the system aims to reduce residual tumor burden and improve patient outcomes, while also addressing healthcare disparities through cost-effective, portable technology. Founded in 2019 and headquartered in Philadelphia, the company is currently in Phase 1 clinical development, targeting multiple solid tumor indications. Integro's approach has the potential to transform standard-of-care oncologic surgery by providing an accessible, scalable solution that increases surgical accuracy and reduces recurrence rates. With a pipeline focused on high-need cancers, the company is positioned at the forefront of theranostics and precision oncology.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 Interim Data Readout70% success
• Q4 2026Orphan Drug Designation for CXL in Sarcoma80% success
• Q2 2026Series A Financing Close60% success